(Total Views: 139)
Posted On: 09/08/2022 10:15:49 AM
Post# of 25314
$REGN News Article - Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals https://marketwirenews.com/news-releases/afli...63271.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼
